TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Jenna Bosco - Senior Vice President of Corporate Communications Conference Call Participants Michael DiFiore - Evercore Ed White - H.C. Wainright Matt Kaplan - Ladenburg Thalmann Prakhar Agrawal - Cantor Fitzgerald William Wood - B. Riley Securities Operator ...

Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today, February 28, 2024, at 8:30 AM ET New York, NY, (February 28, 2024) – TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along wit ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEU ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, President, and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Edward White - H.C. Wainright Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Eric Joseph - JPMorgan Prakhar Agrawal - Cantor Fitzgerald Mat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or other jur ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2023 Earnings Call Transcript August 1, 2023 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO and President Adam Waldman - Chief Commercialization Officer Sean Power - CFO, Corporate Secretary and Treasurer Conference Call Participants Eric Joseph - JP Morgan Ed White - H.C. Wainwright Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Michael DiFiore - Evercore Prakhar Agrawal - Cant ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or other ju ...

Financial Data and Key Metrics Changes - The company reported net product revenue of $7.8 million in the first quarter, exceeding internal expectations [31] - The net loss for Q1 2023 was approximately $32.6 million, down more than 50% from $67 million in Q1 2022, reflecting a disciplined spending approach [35] - GAAP net loss for Q1 2023 was $39.4 million or $0.28 per share, compared to a loss of $69 million or $0.51 per share in Q1 2022 [35] Business Line Data and Key Metrics Changes - BRIUMVI's launch has seen early adoption from both major academic centers and community practices, with over 165 physicians from more than 125 centers prescribing the drug [31][32] - The company has achieved coverage policies for over 50% of covered lives across the US, ahead of the mid-year goal [33] Market Data and Key Metrics Changes - The company anticipates an acceleration in prescriptions in the second half of the year as operational hurdles are addressed and the J-Code becomes effective on July 1, 2023 [33] - There is significant growth potential for the CD20 class in the EU, with positive discussions with key opinion leaders in Germany [9] Company Strategy and Development Direction - The company is evaluating its commercial pathway in Europe, considering either a solo launch or a partnership, with a decision expected in the coming months [29] - The company aims to achieve broad access to BRIUMVI with greater than 80% coverage by the end of 2023 [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in BRIUMVI's best-in-class potential and the positive reception from healthcare providers [26][28] - The company believes that operational hurdles will continue to improve throughout the year, facilitating further growth [33] Other Important Information - The company ended the quarter with approximately $160 million in cash, which is expected to last into mid-2024 based on current revenue assumptions [30][36] - The company has capitalized $25 million in inventory on the balance sheet, which will likely be the sole campaign in 2023 [15] Q&A Session Summary Question: Can you elaborate on the mix between new to CD20 versus switches? - The company is seeing a mix of both naive and switch patients, with a broad distribution from various therapies [40][41] Question: What percentage of patients are utilizing the patient access programs? - Approximately 10% to 15% of free goods were provided, primarily through the quick-start program [49] Question: What are the expectations for R&D and SG&A expenses throughout the year? - R&D is expected to remain consistent with Q1 levels, while SG&A is also anticipated to stay stable [50][51] Question: How many patients were infused in the first quarter? - The company does not have exact numbers on infusions, as they only track prescriptions that go through the hub [55][56] Question: What was the gross to net discount for this quarter? - The gross to net discount in Q1 was 77%, with expectations for fluctuations in future quarters [60]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number 1-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...

Financial Data and Key Metrics Changes - The GAAP net loss for the year ended December 31, 2022, was $198 million or $1.46 per share, a decrease from a net loss of $348 million or $2.63 per share in 2021, reflecting a year-over-year decrease of approximately $150 million due to streamlined efforts [32] - The GAAP net loss for Q4 2022 was approximately $53 million or $0.39 per share, down from a net loss of approximately $93 million or $0.70 per share in Q4 2021, driven by a disciplined spending approach [53] Business Line Data and Key Metrics Changes - BRIUMVI received FDA approval to treat adult patients with relapsing forms of multiple sclerosis (RMS), marking a significant milestone for the company [4] - The launch of BRIUMVI is focused on building awareness, driving utilization, and minimizing access barriers, with early feedback indicating significant interest from healthcare providers [10][12] Market Data and Key Metrics Changes - Approximately 35% of covered lives in the U.S. now have payer coverage for BRIUMVI, ahead of internal goals [13] - The company estimates that nearly 1 million Americans are living with MS, with 75,000 to 80,000 seeking new treatment each year, indicating a substantial market opportunity [24] Company Strategy and Development Direction - The company aims to achieve coverage for the majority of covered lives in the U.S. by the first half of 2023, with a long-term goal of reaching 80% to 90% coverage by the end of the year [75] - The company is investing in a mix of promotional resources, including in-person and virtual marketing, to support the launch of BRIUMVI [48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early launch activities of BRIUMVI, noting that initial successes are ahead of schedule and position the company for an exciting year of commercial execution [99] - The company is focused on minimizing access barriers and achieving optimal patient access to BRIUMVI, with positive early feedback from infusion centers [50][51] Other Important Information - The company ended 2022 with approximately $220 million in cash, cash equivalents, and investment securities, including $45 million of available capacity under its Hercules facility [15] - Operating expenses for 2023 are expected to average approximately $40 million to $50 million per quarter, excluding BRIUMVI inventory build [16] Q&A Session Summary Question: What is the initial dosing protocol for patients switching from other anti-CD20 therapies? - Patients switching will go through the four-hour starting dose as per label, with a switch study planned to evaluate the necessity of this protocol [36][39] Question: What percentage of patients are utilizing patient assistance programs? - A higher percentage of patients are expected to engage with assistance programs in the first half of the year, which should decrease over time as coverage improves [42] Question: What is the company's strategy regarding the European market? - The company anticipates being six to nine months behind in the European market and is evaluating whether to partner or handle it independently [60] Question: How is the sales force currently structured? - The company feels that its sales force is appropriately sized for the current opportunity, with ongoing evaluations to ensure effectiveness [79][80] Question: What is the cash position and expected R&D and G&A mix for 2023? - The cash position at the end of Q4 2022 was $220 million, with operating expenses expected to be weighted towards SG&A rather than R&D [89]